rhIGFBP-3 Completed Phase 2 Trials for Retinopathy of Prematurity (ROP) Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT01096784IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity